Understanding the control of expression levels of EGLNs and HIF1A in HNSCC pathogenesis may provide insight for potential therapeutic strategies aimed at targeting hypoxia signaling pathways to improve patient outcomes. This evidence concerns the gene HIF1A and head and neck squamous cell carcinoma.